Providers' Perspectives on Implementation of Low-threshold HCV Treatment in New York State: A Qualitative Study
- PMID: 40276722
- PMCID: PMC12019634
- DOI: 10.1093/ofid/ofaf184
Providers' Perspectives on Implementation of Low-threshold HCV Treatment in New York State: A Qualitative Study
Abstract
Background: Global study data show injection drug use is driving upwards of 79% of all new hepatitis C virus (HCV) cases in high-income countries. Low-threshold models can engage vulnerable populations in treatment to achieve HCV elimination targets. We examined the implementation of low-threshold models for HCV care in New York State, which has a robust HCV elimination program.
Methods: We conducted semi-structured interviews with 16 healthcare providers in 2022. Included providers either self-described as "low-threshold," had a clinical focus on marginalized populations, or practiced in non-traditional settings. Interviews focused on the implementation of low-threshold HCV care. Transcripts were analyzed using thematic analysis and were categorized into themes guided by the Exploration, Preparation, Implementation, Sustainment (EPIS) framework.
Results: Providers implemented low-threshold HCV care by facilitating access (e.g., having walk-in or telemedicine HCV services). Point-of-care testing and peer support were other important features. The inner context was driven by provider and organization values and involved providing low-threshold HCV care within health systems that were not themselves "low-threshold." Adequate staffing was crucial for the extensive care coordination and outreach activities needed to engage persons who inject drugs (PWID). The outer context was characterized by a limited funding environment, restrictive insurance policies, and the high impact of patients' unmet social needs. Providers relied on care coordination and integrated care models to overcome these barriers.
Conclusions: Low-threshold HCV care incorporates operational flexibility and patient navigation but is challenged by patients' unmet social needs. Jurisdictions can support implementation by providing adequate funding for substantial outreach activities needed to engage vulnerable populations.
Keywords: hepatitis C; implementation; injection drug use; qualitative; substance use disorder.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
Similar articles
-
How to Implement Digital Clinical Consultations in UK Maternity Care: the ARM@DA Realist Review.Health Soc Care Deliv Res. 2025 May;13(22):1-77. doi: 10.3310/WQFV7425. Health Soc Care Deliv Res. 2025. PMID: 40417997 Review.
-
"Treated like a Human Being": perspectives of people who inject drugs attending low-threshold HCV treatment at a syringe service program in New York City.Harm Reduct J. 2023 Jul 27;20(1):95. doi: 10.1186/s12954-023-00831-9. Harm Reduct J. 2023. PMID: 37501180 Free PMC article.
-
Rapid molecular tests for tuberculosis and tuberculosis drug resistance: a qualitative evidence synthesis of recipient and provider views.Cochrane Database Syst Rev. 2022 Apr 26;4(4):CD014877. doi: 10.1002/14651858.CD014877.pub2. Cochrane Database Syst Rev. 2022. PMID: 35470432 Free PMC article.
-
Health professionals' experience of teamwork education in acute hospital settings: a systematic review of qualitative literature.JBI Database System Rev Implement Rep. 2016 Apr;14(4):96-137. doi: 10.11124/JBISRIR-2016-1843. JBI Database System Rev Implement Rep. 2016. PMID: 27532314
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
References
-
- Centers for Disease Control and Prevention . Viral hepatitis surveillance report 2022. Centers for Disease Control and Prevention; 2024. Available at: https://www.cdc.gov/hepatitis-surveillance-2022/about/index.html.
-
- Degenhardt L, Charlson F, Stanaway J, et al. Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. Lancet Infect Dis 2016; 16:1385–98. - PubMed
-
- World Health Organization . Global health sector strategy on viral hepatitis 2016–2021. Geneva, Switzerland: World Health Organization, 2016.
-
- New York State Department of Health . New York state hepatitis C elimination plan 2018. Available at: https://www.health.ny.gov/diseases/communicable/hepatitis/hepatitis_c/el....
Grants and funding
LinkOut - more resources
Full Text Sources